



Poly Medicure Ltd.

Works : Plot No. 104-105, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad-121004, INDIA
Phone : +91-129-4287000, 3355070, Fax : +91-129-2307007, 2309102
E-mail : info@polymedicure.com, Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

POLYMED
Medical Devices

04.02.2015

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject:- Outcome of the Meeting of the Board of Director held on today i.e 4th February, 2015

Ref:- Un-Audited Financial Results for the third quarter/nine months ended on 31st December, 2014

Dear Sir/Madam,

Please be informed that, pursuant to the provisions of the Listing Agreement entered with the Stock Exchange(s), the Board of Directors at its meeting held on today i.e 4th February, 2015 has approved the Un-Audited Financial Results of the Company for the Third quarter/nine months ended on 31st December, 2014.

Accordingly, please find attached herewith the Un-Audited Financial Results of the Company for the Third quarter/nine months ended on 31st December, 2014 alongwith Limited Review Report.

This is for your information and record.

For Poly Medicure Limited

Vinay



Vinay Gujral
Company Secretary
Enclosed:- As above

POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020, Phone: 011-26321889, Fax: 011-26321894
 Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE ENDED 31ST DECEMBER, 2014
Part I

Particulars	Quarter ended			Year to date Ended		₹ in lacs
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	Year Ended
	(Unaudited)			(Unaudited)		(Audited)
1 Income from operations						
a Net sales / income from operations (net of excise duty)	9,577.10	9,386.63	7,841.24	27,097.09	22,402.98	30,483.09
b Other operating income	158.50	177.37	188.04	481.46	646.68	750.23
Total income from operations (net)	9,735.60	9,564.00	8,029.28	27,578.55	23,049.66	31,233.32
2 Expenses						
a Cost of materials consumed	3,642.36	3,413.60	2,597.87	9,812.14	7,375.93	10,085.67
b Purchases of stock-in-trade	177.63	211.84	123.98	545.11	491.92	575.91
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	(269.55)	(349.04)	109.59	(591.74)	(109.52)	(347.48)
d Employee benefits expense	1,589.85	1,588.70	1,257.17	4,551.06	3,650.89	4,980.36
e Depreciation and amortisation expense	478.41	447.46	339.38	1,326.51	978.54	1,351.06
f Other expenses	2,381.36	2,442.80	2,253.88	6,930.03	6,024.03	8,675.50
Total expenses	8,000.06	7,755.36	6,681.87	22,573.11	18,411.79	25,321.02
3 Profit from operations before other income, finance costs and exceptional items (1-2)	1,735.54	1,808.64	1,347.41	5,005.44	4,637.87	5,912.30
4 Other income	397.35	186.24	4.41	698.73	45.89	106.20
5 Profit from ordinary activities before finance costs and exceptional items (3 + 4)	2,132.89	1,994.88	1,351.82	5,704.17	4,683.76	6,018.50
6 Finance costs	279.95	174.20	202.84	648.52	503.78	794.87
7 Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,852.94	1,820.68	1,148.98	5,055.65	4,179.98	5,223.63
8 Exceptional items	-	1,957.80	370.80	1,957.80	370.80	991.46
9 Profit from ordinary activities before tax (7 + 8)	1,852.94	3,778.48	1,519.78	7,013.45	4,550.78	6,215.09
10 Tax expense	659.70	1,051.21	413.80	2,122.10	1,385.87	1,911.88
11 Net Profit from ordinary activities after tax (9 - 10)	1,193.24	2,727.27	1,105.98	4,891.35	3,164.91	4,303.21
12 Extraordinary items	-	-	-	-	-	-
13 Net Profit for the period (11 + 12)	1,193.24	2,727.27	1,105.98	4,891.35	3,164.91	4,303.21
14 Paid-up equity share capital (Face Value of ₹ 10 each)	2,205.67	2,204.14	2,203.32	2,205.67	2,203.32	2,203.32
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	12,226.21
16 Earnings per share (before extraordinary items) (not annualised)						
Basic (₹)	5.38	12.38	5.01	22.18	14.36	19.53
Diluted (₹)	5.38	12.37	5.01	22.18	14.35	19.51


Munawar H. P.

Part II - Select information for the Quarter ended December 31, 2014

A PARTICULARS OF SHAREHOLDING							
1	Public shareholding						
	Number of shares	11,331,282	11,315,982	11,307,773	11,331,282	11,307,773	11,307,773
	Percentage of shareholding	51.37%	51.34%	51.32%	51.37%	51.32%	51.32%
2	Promoters and Promoter Group Shareholding						
	a) Pledged / Encumbered						
	Number of shares	-	-	-	-	-	-
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non - encumbered						
	Number of shares	10,725,438	10,725,438	10,725,438	10,725,438	10,725,438	10,725,438
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	48.63%	48.66%	48.68%	48.63%	48.68%	48.68%
B	Investor Complaints						
	Pending at the beginning of the quarter	Nil					
	Received during the quarter	Nil					
	Disposed of during the quarter	Nil					
	Remaining unresolved at the end of the quarter	Nil					

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 4th February 2015.
- During the quarter ended December 2014, 15300 equity shares of ₹ 10 each issued under employee stock option scheme were got listed and admitted to dealings on the stock exchanges from 21st November 2014.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- Effective from 1st April 2014, the Company has revised depreciation rate on fixed assets as per the useful life specified in the Companies Act, 2013. Based on current estimates, depreciation of ₹ 60.66 lacs on account of assets whose useful life is already exhausted as on 1st April, 2014 and deferred tax of ₹ 20.62 lacs thereon have been adjusted to opening reserves. Had there not been any change in useful life of assets, depreciation charged for the quarter and nine months ended 31st December 2014 would have been lower by ₹ 10.90 lacs and ₹ 23.97 lacs respectively.
- The equity shares of the company have been sub divided having a face value of ₹ 5 each from ₹ 10 each on record date i.e. 3rd February 2015.
- The statutory Auditors have carried out the limited review of the above results.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

By order of the Board




Himanshu Baid

Managing Director

Place : New Delhi

Date : 04.02.2015



DOOGAR & ASSOCIATES

Chartered Accountants


Limited Review Report

The Board of Directors
Poly Medicure Limited
232B, 3rd Floor, Okhla Industrial Estate
Phase III
New Delhi – 110 020

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended December 31st, 2014 except for the disclosures regarding "Public Shareholding" and "Promoters and Promoters Group Shareholding" which have been traced from disclosures made by the Management and have not been audited by us. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
(Reg. No. 000561N)


M.S. Agarwal
(Partner)
M. No. 86580

Place: New Delhi
Date: 4th February, 2015.